Multi-modal prostate cancer marker

A computer-implemented method of predicting disease progression in patient with prostate cancer, the method comprising:

• a) receiving, at at least one processor, data reflecting at least 2 patient biomarkers regarding the prostate cancer tumor selected from the group consisting of:
• T category, ACTL6B methylation, TCERGL1 methylation, chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations;
• b) constructing, at the at least one processor, an expression profile corresponding to the expression levels;
• c) comparing, at the at least one processor, said patient biomarkers to corresponding reference or control biomarkers;
• d) determining, at the at least one processor, the likelihood of disease progression;
• wherein a likelihood of disease progression is higher with each of ACTL6B hyper-methylation, TCERGL1 hypo-methylation, higher T category, and higher incidences of chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations, when the difference is statistically significant on comparison with the reference or control biomarkers.

A device for predicting disease progression in patient with prostate cancer, the device comprising:

• at least one processor;
• and
• electronic memory in communication with the at least one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to:
• a) receive data reflecting at least 2 patient biomarkers regarding the prostate cancer tumor selected from the group consisting of:
• T category, ACTL6B methylation, TCERGL1 methylation, chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations;
• b) compare said patient biomarkers to corresponding reference or control biomarkers;
• and
• c) determine, at the at least one processor, the likelihood of disease progression;
• wherein a likelihood of disease progression is higher with each of ACTL6B hyper-methylation, TCERGL1 hypo-niethylation, higher T category, and higher incidences of chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations, when the difference is statistically significant on comparison with the reference or control biomarkers.